Search Orphan Drug Designations and Approvals
-
| Generic Name: | raxibacumab | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | ABthraxTM | ||||||||||||||||
| Date Designated: | 11/12/2003 | ||||||||||||||||
| Orphan Designation: | Treatment of anthrax | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Human Genome Sciences, Inc. 14200 Shady Grove Road Rockville, Maryland 20850 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | raxibacumab |
|---|---|---|
| Trade Name: | ABthraxTM | |
| Marketing Approval Date: | 12/14/2012 | |
| Approved Labeled Indication: | Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, | |
| Exclusivity End Date: | 12/14/2019 | |
| Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







